Congressman Steve Womack (AR-3)—along with U.S. Senators John Boozman and Tom Cotton—released the following statement regarding the announcement that NOWDiagnostics received an Emergency Use Authorization (EUA) for its ADEXUSDx COVID-19 antibody test for use in moderate-complex settings and at the point-of-care from the U.S. Food and Drug Administration (FDA). The Springdale-based company developed and manufactures the fingerstick technology, which provides laboratory quality results in minutes using a revolutionary platform, in Northwest Arkansas:
The lawmakers said, “Thanks to the incredible work of NOWDiagnostics, the only U.S.-made antibody test of its kind was developed and manufactured here in Springdale. And while every Arkansan should be proud of our state’s contribution to America’s health, unfortunately, slow FDA approval prevented its earlier release. We will work together to ensure the FDA prioritizes a more efficient review process.”
Congressman Steve Womack (AR-3) has represented Arkansas’s Third Congressional District since 2011. He is a member of the House Appropriations Committee.
Original source can be found here.
